OncoMatch/Clinical Trials/NCT05753826
Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
Is NCT05753826 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Adebrelimab and Fuzuloparib for ovarian neoplasms.
Treatment: Adebrelimab · Fuzuloparib — This is a single-arm, exploratory study. People with recurrent platinum-resistant ovarian cancer who have not received any previous systemic antitumor therapy for ovarian cancer were selected to evaluate the efficacy and safety of adebrelimab combined with fuzuloparib.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
recurrence within less than 6 months after the last treatment with platinum-containing chemotherapy
Cannot have received: immune checkpoint inhibitor
prior treatment with known or probable immune checkpoint inhibitors
Lab requirements
Blood counts
HB≥100g/L, WBC≥3×10^9/L, ANC≥1.5×10^9/L, PLT≥100×10^9/L (no blood transfusion within 14 days)
Kidney function
Serum Cr≤1.5x ULN
Liver function
BIL ≤1.5x ULN; ALT and AST≤2.5x ULN, ALT and AST≤5x ULN in patients with liver metastases
Cardiac function
No severe heart disorders; APTT ≤ 1.5x ULN, PT ≤ 1.5x ULN, INR ≤ 1.5x ULN unless on anticoagulation and within expected range; No cardiac insufficiency above NYHA grade 2, unstable angina, acute MI within 1 year, clinically significant arrhythmias requiring treatment, QTc>470ms
Major organ functions are normal and meet the following criteria: (1) Blood routine inspection standards must meet: (no blood transfusion within 14 days)a.HB≥100g/L, b. WBC≥3×10^9/L c. ANC≥1.5×10^9/L, d.PLT≥100×10^9/L; (2) Biochemical examination must meet the following standards: a. BIL ≤1.5 times the upper limit of normal (ULN); b. ALT and AST≤2.5×ULN, ALT and AST≤5×ULN in patients with liver metastases; c. Serum Cr≤1.5×ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 times ULN, prothrombin time (PT) ≤ 1.5 times ULN, international normalized ratio (INR) ≤ 1.5 times ULN, unless the patient is receiving anticoagulation, as long as PT or APTT is within the expected range of anticoagulant use; No severe heart, lung, liver or kidney disorders
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05753826 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune checkpoint inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages